PE Tech Report


Like this article?

Sign up to our free newsletter

Arlington Capital invests in Everest Clinical Research Corporation

Arlington Capital Partners (Arlington Capital), a Washington, DC-based private equity firm, has made a majority investment in Everest Clinical Research Corporation (Everest), alongside the company’s founding shareholders and senior management who will continue to lead the firm.”Founded in 2004 and headquartered in Toronto, Canada, Everest is a leading contract research organisation (CRO) providing a comprehensive suite of mission-critical clinical research services to the worldwide pharmaceutical, biotechnology, and medical device industries across Phase I-IV trials. Throughout the Company’s history, Everest has focused on providing exceptional quality, customer service, and on-time delivery to its partners to advance life-changing research. Everest employs over 300 employees across its Toronto, Ontario, Canada; Little Falls, New Jersey, USA; and Shanghai, China offices.

Malcolm Little, a Partner at Arlington, says: “We are excited to embark upon this new partnership with the impressive Everest team. Everest has built an exceptional organisation predicated on continuous innovation, technical excellence, and unwavering quality and customer support. Everest’s expertise in biostatistics and clinical data management together with the Company’s extensive track record of supporting many of the world’s most successful pharmaceutical companies across a diverse array of therapeutic areas and clinical phases provides a strong platform for further growth.”
“We are overjoyed to partner with Arlington as we step forward into our next phase of growth,” says Irene Zhang, Founder and CEO of Everest. “We chose to partner with Arlington because of its long track record of success investing in and scaling healthcare businesses, its deep expertise in the pharmaceutical services sector, and its reputation for partnering with founder-owned and operated businesses. We are extremely pleased to work together with Arlington as they share our vision for expanding Everest’s capabilities to better serve our customers while at the same time maintaining our unique culture. Arlington’s ability to provide significant strategic and financial support will further enable Everest to expand our service lines, grow our employee base, and most importantly, provide best-in-class support to our customers throughout the lifecycle of their clinical trials.”
Erica Son, a Vice President at Arlington, adds: “We have been very impressed by the Company’s long track record of outstanding bookings and backlog growth, both of which have grown consistently with new and existing customers through the ongoing Covid-19 pandemic. Furthermore, the Company’s diversified backlog provides significant revenue visibility and embedded growth opportunities.”

Like this article? Sign up to our free newsletter




Blackstone Private Equity